Clinical trials
Phase 1 Body Weight trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Unknown status | 6 |
| Recruiting | 3 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Manitoba | 2 |
| Baskaran Chandrasekaran | 1 |
| Beta-Stim Ltd. | 1 |
| Carmot Therapeutics, Inc. | 1 |
| Corbus Pharmaceuticals Inc. | 1 |
| Eli Lilly and Company | 1 |
| Kyowa Kirin Co., Ltd. | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| MBX Biosciences | 1 |
| Mando Group AB | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Body Weight | 25 |
| Obesity | 8 |
| Overweight | 6 |
| Diabetes Mellitus | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Metabolic Diseases | 3 |
| Nutrition Disorders | 3 |
| Cardiovascular Diseases | 2 |
| Endocrine System Diseases | 2 |
| Hyperlipidemias | 2 |
Trials
Showing 51 to 25 of 25. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.